Advancing Translational Research with RNA Expression Intelligence
From discovery to validated gene-expression panels, iXpressGenes delivers objective molecular endpoints for research, clinical studies, and multi-site programs.
- Whole-transcriptome discovery → targeted panels
- CLIA/CAP validated LDT deployment
- Rapid development for real-world research timelines
Turning RNA Data Into Actionable Research Endpoints
iXpressGenes converts candidate gene targets and whole-transcriptome data into analytically validated gene-expression panels and CLIA/CAP laboratory-developed tests that generate objective, evidentiary molecular endpoints for translational and research programs.
Our work is centered on measuring RNA expression in peripheral blood and translating those measurements into standardized, publication-grade outputs for hypothesis testing, longitudinal cohorts, translational initiatives, and multi-site studies.
This gives research teams a pathway from discovery or predefined targets to reproducible assays that can support mechanistic investigation, interventional endpoints, and scalable deployment across study populations.
CLIA-Certified. CAP-Accredited. Research-Ready.
iXpressGenes operates a CLIA-certified, CAP-accredited laboratory in Huntsville, Alabama, deploying assays as validated LDTs designed for reproducible cross-site use in research and translational contexts.
From Finalized Gene List to Validated Panel in About Four Weeks
Our streamlined, project-driven development workflow is built to move rapidly from a discovered signature or finalized target list to a deployable gene-expression panel with bench work, QC, and CLIA/CAP validation built into the timeline.
Target Definition
Begin with investigator-provided genes, candidate targets, or transcriptomic signatures identified through discovery work.
Assay Design & Bench Work
Translate targets into a focused RT-qPCR or multiplex transcriptional panel designed for robust analytical performance.
QC & Validation
Complete bench validation, quality control, and CLIA/CAP-aligned analytical checks to support reproducibility.
Deployable LDT Output
Deliver a validated panel ready for translational studies, longitudinal research, or multi-site implementation.
From Whole Transcriptome Discovery to Focused, Scalable Panels
Beyond rapid panel design from investigator-supplied gene lists, iXpressGenes brings deep sequencing and bioinformatics capability to identify reproducible disease- or phenotype-associated RNA fingerprints and convert them into deployable assays.
Whole-transcriptome sequencing on selected populations or phenotype-defined subsets.
Rigorous QC, alignment, differential expression, pathway analysis, and marker selection.
Extraction of reproducible RNA fingerprints associated with disease states or intervention response.
Conversion into focused RT-qPCR or multiplex panels for scalable testing and objective endpoints.
Ribosomal RNA Depletion
Applied when appropriate to maximize transcriptome coverage for discovery workflows.
Poly-A Selection
Used as appropriate based on project goals, specimen characteristics, and sequencing objectives.
Illumina-Class Sequencing
High-quality sequencing platforms and high read depth support robust transcriptomic interrogation.
Marker Selection Workflows
Structured pipelines prioritize reproducible biomarkers with translational and deployment potential.
Rigorous, Reproducible, and Built to Scale
iXpressGenes combines next-generation sequencing, standardized RNA quality control, and proven bioinformatic workflows to discover, validate, and operationalize multi-marker expression signatures.
Core Analytical Capabilities
- RNA quality control and standardized preprocessing
- Read alignment and transcript quantification
- Differential expression analysis
- Functional and pathway annotation
- Multi-marker signature extraction
Research Outcomes Enabled
- Discovery of novel, reproducible expression fingerprints
- Validation across additional samples and cohorts
- Translation into deployable gene-expression panels
- Support for broader research or clinical implementation
- Objective endpoints for translational programs
Demonstrated Across a Broad Translational Research Landscape
Company materials and collaborative projects reflect applied work across behavioral, neurological, inflammatory, and cardiometabolic research domains, with additional flexibility for emerging translational areas.
Mental Health & Inflammation
Objective measurement of inflammation reduction and transcriptomic change in cognitive behavioral therapy, vagal or autonomic modulation, breathwork, and nutritional or supplementation intervention studies.
Obsessive-Compulsive Disorder (OCD)
Support for deep sequencing, bioinformatic analysis, TAI testing, and the development of OCD-specific or minimal viable panels derived from identified RNA fingerprints.
TBI & Neurodegeneration
Development of panels targeting neuroinflammatory pathways, blood-brain barrier integrity, inflammasome activation, and axonal injury-related biology.
Cardiometabolic & Endocrine Research
Use of transcriptional readouts aligned to inflammatory and metabolic biology in studies related to cardiac risk, hypertension, diabetes, and related endpoints.
Built for Collaboration Across Academic, Government, and Commercial Research
iXpressGenes partners with commercial entities, academic institutions, and government organizations to design, validate, and deploy transcriptional panels that fit real research programs and translational objectives.
Our model supports collaboration from discovery through validation and deployment, making it possible to move from hypothesis generation to practical molecular endpoints within a single integrated workflow.
What Sets iXG Apart in Translational RNA Research
Focused on upstream biological insight through peripheral blood gene-expression measurement.
Accelerated pathway from finalized targets to analytically validated, deployable panels in routine projects.
Discovery, validation, and deployment capability under one integrated laboratory and bioinformatics framework.
Bring Objective Molecular Endpoints to Your Research Program
Accelerate discovery, validate faster, and measure what matters with a partner built to translate RNA expression data into real-world research tools.